FDA’s VRBPAC votes in favor of adapting the Covid-19 vaccine to the latest Omicron variant

The FDA’s Vaccine and Related Biological Products Advisory Committee on Tuesday gave the thumbs up — by a vote of 19-2 — that the FDA should require an Omicron-related component in this next season’s booster dose for Covid-19, which both Pfizer/BioNTech and Moderna are hard at work on.

Wayne Marasco

And while neither booster will likely be ready to go with adequate supplies for all American adults by the beginning of the next school year, the situation is still complex and fluid, with CBER Director Peter Marks telling the committee that it’ll take companies at least three months to ready their supplies for this expected next wave.

“Right now the critical thing is the manufacturers need to know what to put into their vaccines,” Marks said. Over the coming months, there will be debate over who is most appropriate for a booster, but it seems…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.